INTRODUCTION AND OBJECTIVE: The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC) that accounts for 70-80% of all renal malignancies. To date, no useful markers are available in clinical practice for early diagnosis and for optimal patient stratification. MicroRNAs, a class of small non-coding RNA, are emerging as promising molecules in the management of urological tumors suggesting the possibility of using them as non-invasive biomarkers. The aim of this study is to evaluate whether miR-210-3p may be an accurate non invasive diagnostic and prognostic biomarker for ccRCC patients. METHODS: This study includes a cohort of 21 ccRCC cases underwent radical or partial nephrectomy. We analyzed by RTpPCR miR-210-3p levels in neoplastic and healthy tissues and in urine specimens collected at surgery and during follow-up visits (from 3 to 24 months) of all ccRCC cases, of which 18 disease-free patients and a small subgroup presenting metastatic progression. Urine samples were also collected from 16 healthy donors with similar demographic features. The specimens were frozen within 30 minutes from collection and stored at -80C until RNA extraction and microRNA expression analysis. RESULTS: miR-210-3p was upregulated in ccRCC frozen tissues compared to matched normal counterparts. Next, we evidenced that miR-210-3p resulted significantly up-regulated in urine specimens collected from ccRCC patients at the time of surgery, compared to healthy samples. Of note, miR- 210-3p levels resulted significantly reduced in urine samples from disease-free patients during follow-up, compared to the baseline levels (time of surgery). In a small subgroup of patients presenting metastases, the urine levels of miR-210-3p increased and, interestingly, again decreased when responding to medical treatments. CONCLUSIONS: This pilot study highlights the relevance of secreted miR-210-3p as powerful non invasive diagnostic and prognostic biomarker for ccRCC patients, with potential clinical applications from diagnosis to treatment.
LIQUID BIOPSY IN CLEAR CELL RENAL CELL CARCINOMA: URINARY MIR-210-3P AS EMERGING SPECIFIC BIOMARKER / Costantini, M; Petrozza, V; Tito, C; Giammusso, Lm; Sorrentino, V; Cacciotti, J; Porta, N; Iaiza, A; Pastore, Al; Di Carlo, A; Simone, G; Gallucci, M; Carbone, A; Fazi, F. - In: THE JOURNAL OF UROLOGY. - ISSN 0022-5347. - 203:(2020), pp. E107-E107. (Intervento presentato al convegno Annual Meeting of the American-Urological-Association (AUA) tenutosi a Washington, DC).
LIQUID BIOPSY IN CLEAR CELL RENAL CELL CARCINOMA: URINARY MIR-210-3P AS EMERGING SPECIFIC BIOMARKER
Petrozza, V;Tito, C;Iaiza, A;Pastore, AL;Di Carlo, A;Gallucci, M;Carbone, A;Fazi, F
2020
Abstract
INTRODUCTION AND OBJECTIVE: The most common subtype of renal cell carcinoma (RCC) is clear cell RCC (ccRCC) that accounts for 70-80% of all renal malignancies. To date, no useful markers are available in clinical practice for early diagnosis and for optimal patient stratification. MicroRNAs, a class of small non-coding RNA, are emerging as promising molecules in the management of urological tumors suggesting the possibility of using them as non-invasive biomarkers. The aim of this study is to evaluate whether miR-210-3p may be an accurate non invasive diagnostic and prognostic biomarker for ccRCC patients. METHODS: This study includes a cohort of 21 ccRCC cases underwent radical or partial nephrectomy. We analyzed by RTpPCR miR-210-3p levels in neoplastic and healthy tissues and in urine specimens collected at surgery and during follow-up visits (from 3 to 24 months) of all ccRCC cases, of which 18 disease-free patients and a small subgroup presenting metastatic progression. Urine samples were also collected from 16 healthy donors with similar demographic features. The specimens were frozen within 30 minutes from collection and stored at -80C until RNA extraction and microRNA expression analysis. RESULTS: miR-210-3p was upregulated in ccRCC frozen tissues compared to matched normal counterparts. Next, we evidenced that miR-210-3p resulted significantly up-regulated in urine specimens collected from ccRCC patients at the time of surgery, compared to healthy samples. Of note, miR- 210-3p levels resulted significantly reduced in urine samples from disease-free patients during follow-up, compared to the baseline levels (time of surgery). In a small subgroup of patients presenting metastases, the urine levels of miR-210-3p increased and, interestingly, again decreased when responding to medical treatments. CONCLUSIONS: This pilot study highlights the relevance of secreted miR-210-3p as powerful non invasive diagnostic and prognostic biomarker for ccRCC patients, with potential clinical applications from diagnosis to treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
